European Heart Journal

Ricardo Ladeiras-Lopes, Rafael Vidal-Perez, Diogo Santos-Ferreira, Michael Alexander, Lavinia Baciu, Sarah Clarke, Filippo Crea, Thomas Felix LÃ¼scher

doi : 10.1093/eurheartj/ehac150

European Heart Journal, Volume 43, Issue 19, 14 May 2022, Pages 1794â€“1798

The association between the dissemination of scientific articles on Twitter and online visibility (as assessed by the Altmetric Score) is still controversial, and the impact on citation rates has never been rigorously addressed for cardiovascular medicine journals using a randomized design. The ESC Journals Study randomized 695 papers published in the ESC Journal Family (March 2018â€“May 2019) for promotion on Twitter or to a control arm (with no active tweeting from ESC channels) and aimed to assess whether Twitter promotion was associated with an increase in citation rates (primary endpoint) and of the Altmetric Score. This is the final analysis including 694 articles (one paper excluded due to retraction). After a median follow-up of 994 days (interquartile range: 936â€“1063 days), Twitter promotion of articles was associated with a 1.12 (95% confidence interval: 1.08â€“1.15) higher rate of citations, and this effect was independent of the type of article. Altmetric Attention Score and number of users tweeting were positive predictors for the number of citations. A social media strategy of Twitter promotion for cardiovascular medicine papers seems to be associated with increased online visibility and higher numbers of citations.

خرید پکیج و مشاهده آنلاین مقاله

Targeting the CCL2â€“CCR2 axis for atheroprotection

Marios K Georgakis, JÃ¼rgen Bernhagen, Laura H Heitman, Christian Weber, Martin Dichgans

doi : 10.1093/eurheartj/ehac094

European Heart Journal, Volume 43, Issue 19, 14 May 2022, Pages 1799â€“1808

Decades of research have established atherosclerosis as an inflammatory disease. Only recently though, clinical trials provided proof-of-concept evidence for the efficacy of anti-inflammatory strategies with respect to cardiovascular events, thus offering a new paradigm for lowering residual vascular risk. Efforts to target the inflammasomeâ€“interleukin-1Ùƒâ€“interleukin-6 pathway have been highly successful, but inter-individual variations in drug response, a lack of reduction in all-cause mortality, and a higher rate of infections also highlight the need for a second generation of anti-inflammatory agents targeting atherosclerosis-specific immune mechanisms while minimizing systemic side effects. CC-motif chemokine ligand 2/monocyte-chemoattractant protein-1 (CCL2/MCP-1) orchestrates inflammatory monocyte trafficking between the bone marrow, circulation, and atherosclerotic plaques by binding to its cognate receptor CCR2. Adding to a strong body of data from experimental atherosclerosis models, a coherent series of recent large-scale genetic and observational epidemiological studies along with data from human atherosclerotic plaques highlight the relevance and therapeutic potential of the CCL2â€“CCR2 axis in human atherosclerosis. Here, we summarize experimental and human data pinpointing the CCL2â€“CCR2 pathway as an emerging drug target in cardiovascular disease. Furthermore, we contextualize previous efforts to interfere with this pathway, scrutinize approaches of ligand targeting vs. receptor targeting, and discuss possible pathway-intrinsic opportunities and challenges related to pharmacological targeting of the CCL2â€“CCR2 axis in human atherosclerotic disease.

خرید پکیج و مشاهده آنلاین مقاله

Bone marrow activation in response to metabolic syndrome and early atherosclerosis

Ana Devesa, Manuel Lobo-GonzÙ„lez, Juan MartÙŠnez-Milla, BelÃ©n Oliva, InÃ©s GarcÙŠa-Lunar, Annalaura Mastrangelo, Samuel EspaÙŒa, Javier Sanz, JosÃ© M Mendiguren, Hector Bueno, Jose J Fuster, Vicente AndrÃ©s, Antonio FernÙ„ndez-Ortiz, David Sancho, Leticia FernÙ„ndez-Friera, Javier Sanchez-Gonzalez, Xavier Rossello, Borja Ibanez, Valentin Fuster

doi : 10.1093/eurheartj/ehac102

European Heart Journal, Volume 43, Issue 19, 14 May 2022, Pages 1809â€“1828

Experimental studies suggest that increased bone marrow (BM) activity is involved in the association between cardiovascular risk factors and inflammation in atherosclerosis. However, human data to support this association are sparse. The purpose was to study the association between cardiovascular risk factors, BM activation, and subclinical atherosclerosis.

خرید پکیج و مشاهده آنلاین مقاله

Mischief in the marrow: a root of cardiovascular evil

Peter Libby, Matthias Nahrendorf, Filip K Swirski

doi : 10.1093/eurheartj/ehac149

European Heart Journal, Volume 43, Issue 19, 14 May 2022, Pages 1829â€“1831

خرید پکیج و مشاهده آنلاین مقاله

Vascular dysfunction and increased cardiovascular risk in hypospadias

Angela K Lucas-Herald, Augusto C Montezano, Rheure Alves-Lopes, Laura Haddow, Malika Alimussina, Stuart Oâ€™Toole, Martyn Flett, Boma Lee, S Basith Amjad, Mairi Steven, Katriona Brooksbank, Linsay McCallum, Christian Delles, Sandosh Padmanabhan, S Faisal Ahmed, Rhian M Touyz

doi : 10.1093/eurheartj/ehac112

European Heart Journal, Volume 43, Issue 19, 14 May 2022, Pages 1832â€“1845

Hypogonadism is associated with cardiovascular disease. However, the cardiovascular impact of hypogonadism during development is unknown. Using hypospadias as a surrogate of hypogonadism, we investigated whether hypospadias is associated with vascular dysfunction and is a risk factor for cardiovascular disease.

خرید پکیج و مشاهده آنلاین مقاله

Increased cardiovascular risk in boys born with hypospadias: intriguing observations and remaining questions

Nicolle KrÙ†nkel

doi : 10.1093/eurheartj/ehac152

European Heart Journal, Volume 43, Issue 19, 14 May 2022, Pages 1846â€“1848

خرید پکیج و مشاهده آنلاین مقاله

Soluble lectin-like oxidized low-density lipoprotein receptor-1 predicts premature death in acute coronary syndromes

Simon Kraler, Florian A Wenzl, Georgios Georgiopoulos, Slayman Obeid, Luca Liberale, Arnold von Eckardstein, Olivier Muller, FranÃ§ois Mach, Lorenz RÙ†ber, Sylvain Losdat, Martin O Schmiady, Konstantinos Stellos, Kimon Stamatelopoulos, Giovanni G Camici, Annie Srdic, Francesco Paneni, Alexander Akhmedov, Thomas F LÃ¼scher

doi : 10.1093/eurheartj/ehac143

European Heart Journal, Volume 43, Issue 19, 14 May 2022, Pages 1849â€“1860

خرید پکیج و مشاهده آنلاین مقاله

Soluble LOX-1 levels during acute coronary syndrome: a potent and multifaceted warning sign for cardiovascular risk

Andrei C Sposito

doi : 10.1093/eurheartj/ehac173

European Heart Journal, Volume 43, Issue 19, 14 May 2022, Pages 1861â€“1863

خرید پکیج و مشاهده آنلاین مقاله

Interferon regulatory factor-5-dependent CD11c+ macrophages contribute to the formation of ruptureâ€“prone atherosclerotic plaques

Andreas Edsfeldt, Maarten Swart, Pratibha Singh, Lea Dib, Jiangming Sun, Jennifer E. Cole, Inhye Park, Dania Al-Sharify, Ana Persson, Mihaela Nitulescu,Patricia Das Neves Borges, Christina Kassiteridi, Michael E. Goddard, Regent Lee, Petr Volkov, Marju Orho-Melander, Lars Maegdefessel, Jan Nilsson, Irina Udalova, Isabel Goncalves, Claudia Monaco

doi : 10.1093/eurheartj/ehab920

European Heart Journal, Volume 43, Issue 19, 14 May 2022, Pages 1864â€“1877

Inflammation is a key factor in atherosclerosis. The transcription factor interferon regulatory factor-5 (IRF5) drives macrophages towards a pro-inflammatory state. We investigated the role of IRF5 in human atherosclerosis and plaque stability.

خرید پکیج و مشاهده آنلاین مقاله